📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
0 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
177
AMGN Latest News & AI Sentiment Analysis
0 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 10 ARTICLES
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
BioCryst has achieved profitability while its rare-disease therapeutic Orladeyo generates material cash flows, creating a compelling...
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY
The article reflects a thematic rotation narrative where portfolio managers seek innovation exposure outside the technology sector after...
Amgen: The Market Is Underestimating Its Next Growth Phase (NASDAQ:AMGN)
Amgen appears positioned for an underappreciated growth inflection driven by two key pharmaceutical franchises—Tezspire and Repatha—both...
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
CytomX Therapeutics (CTMX) released Q2 2026 financial results alongside a business update centered on its Varseta-M program, a...
Amgen: First $10 Billion Quarter, More Growth Ahead (NASDAQ:AMGN)
Amgen's Q2 achievement of a $10 billion quarter represents a significant operational milestone for the biopharmaceutical sector,...
Amgen gains after strong quarterly results and continued product momentum
Amgen delivered a meaningful earnings beat in Q2 2026, signaling sustained operational execution across its diversified pharmaceutical...
Amgen Reports Theft of Patient Data in Cyber Incident
Amgen disclosed a significant cybersecurity breach involving unauthorized access to patient data and proprietary information stored on...
Drugmaker Amgen discloses data breach involving patient health information
Amgen disclosed a material data breach affecting patient health information on July 29, representing a cybersecurity incident of...
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
The comparison between XLV and PBE reflects a classic trade-off in healthcare investing: concentrated volatility versus diversified...
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
The molecular glues therapeutic landscape is experiencing significant competitive expansion, with 80+ emerging pipeline candidates...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice